Skip to main content
SpringerLink
Log in

Direct-acting antiviral therapy for hepatitis C saves costs in Italy

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Marcellusi A, et al. Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data. PharmacoEconomics : 30 Oct 2018. Available from: URL: https://doi.org/10.1007/s40273-018-0733-3

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Direct-acting antiviral therapy for hepatitis C saves costs in Italy. PharmacoEcon Outcomes News 816, 10 (2018). https://doi.org/10.1007/s40274-018-5430-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-018-5430-0

Search

Navigation